A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer

NCT04355520 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer

Interventions

DRUG: TQ-B3525
DRUG: Fulvestrant injection

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.